Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cellectis SA completes €19.5mm IPO on Alternext

Executive Summary

A 1999 Institut Pasteur spin-off, Cellectis SA (genome engineering) raised more than the €14.6mm it expected, netting €19.5mm ($25.2mm) in its IPO of 2.1mm shares priced at €10.25 apiece, the high end of the anticipated €8.90-10.25 range. Its stock will trade on the Alternext market of Euronext, Paris.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies